CURRENT TREATMENT OF HEART FAILURE

1 Padfield GJ McMurray JJV. Current treatment of heart failure. J R Coll Physicians Edinb 2006; 36:141–6.

2 Vasan RS EJ Benjamin Prevalence Levy D. features clinical of prognosis diastolic failure: an epidemiological perspective. J Am Coll Cardiol 1995; 26:1565–74.

3 Yusuf S MA Pfeffer ,Swedberg K Effects of candesartan in patients with chronic heart failure and preserved left ventricular ejection fraction: the CHARM-Preserved Trial. Lancet 2003; 362:777–81.

4 Sueta CA A Russo A Schenck DW Brown Simpson RJ. Effect of angiotensin-converting enzyme inhibitor or angiotensin receptor blocker on one-year survival in patients 65 years hospitalised with a left ventricular ejection fraction 50%. Am J Cardiol 2003; 91:363–5.

5 Ball SG AS Hall Murray GD. Angiotensin-converting enzyme inhibitors after myocardial infarction: indications and timing. J Am Coll Cardiol 1995; 25[supplement]:42S–46S.

6The Heart Outcomes Prevention Evaluation Study Investigators. Effects of angiotensin-converting enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000; 342:145–53.

7 Ahmed A A Husain ,Love TE Heart failure, chronic diuretic use, and increase in mortality and hospitalisation: an observational study using propensity score methods. Eur Heart J 2006; 27:1431–9.

8 Pitt B F Zannad Remme WJ The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999; 341:709–17.

9 Pitt B W Remme Zannad F Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003; 348:1309–21.

10 Bauersachs J D Fraccarollo Ertl G Striking increase of natriuresis by low-dose spironolactone in congestive heart failure only in combination with ACE inhibition. Mechanistic evidence in support of RALES. Circulation 2000; 102:2325–8.

11 Ikram H MWW Webster Nicholls MG Combined spironolactone and converting enzyme inhibitor therapy for refractory heart failure. ANZJM 1986; 16:61–3.

12Uchida T,Yamanaga K, Nishikawa M Anti-aldosterone effect of torasemide. Eur J Pharmacol 1991; 205:145–50.

13 Goodfriend TL DL Ball W Oelkers Bahr V. Torasemide inhibits aldosterone secretion in vitro. Life Sci 1998; 63:PL45–50.

14 Lopez B R Querejeta Gonzalez A Effects of loop diuretics on myocardial fibrosis and collagen Type I turnover in chronic heart failure. J Am Coll Cardiol 2004; 43:2028–35.

15 Zile MR Brutsaert DL. New concepts in diastolic dysfunction and diastolic heart failure: Part I: diagnosis, prognosis, and measurements of diastolic function. Circulation 2002; 105:1387–93.

16The atrial fibrillation follow-up investigation of rhythm management (affirm) investigation. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2002; 347:1825–33.

17 Wachtell K M Lehto ,Gerdts E Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol. The Losartan Intervention for End Point Reduction in Hypertension (LIFE) Study. J Am Coll Cardiol 2005; 45:712–9.

18 Little WC MR Zile Klein A Effect of losartan and hydrochlorothiazide on exercise tolerance in exertional hypertension and left ventricular diastolic function. Am J Cardiol 2006; 98:383–5.